Skip to Content
Merck
All Photos(2)

Documents

D7071

Sigma-Aldrich

Dapoxetine hydrochloride

≥98% (HPLC)

Synonym(s):

(S)-N,N-dimethyl-1-phenyl-3-(1-naphthalenyloxy)propanamine hydrochloride, S-(+)-N,N-dimethyl-a-[2-(naphthalenyloxy)ethyl] benzenemethanamine hydrochloride, LY-210448 hydrochloride

Sign Into View Organizational & Contract Pricing
All Photos(2)

About This Item

Empirical Formula (Hill Notation):
C21H23NO · HCl
CAS Number:
129938-20-1
Molecular Weight:
341.87
MDL number:
MFCD08272809
UNSPSC Code:
12352200
PubChem Substance ID:
329798842
NACRES:
NA.77

Assay

≥98% (HPLC)

form

powder

optical activity

[α]/D +125 to +135°, c = 1 in methanol

storage condition

desiccated

color

white

solubility

DMSO: ≥20 mg/mL

originator

Eli Lilly

storage temp.

room temp

SMILES string

Cl.CN(C)[C@@H](CCOc1cccc2ccccc12)c3ccccc3

InChI

1S/C21H23NO.ClH/c1-22(2)20(18-10-4-3-5-11-18)15-16-23-21-14-8-12-17-9-6-7-13-19(17)21;/h3-14,20H,15-16H2,1-2H3;1H/t20-;/m0./s1

InChI key

IHWDIQRWYNMKFM-BDQAORGHSA-N

Gene Information

human ... SLC6A4(6532)

General description

Dapoxetine ((+)-(S)-N,N-dimethyl-(α)-[2(1naphthal enyloxy)ethyl]-benzenemethanamine hydrochloride) possess a similar structure as that of fluoxetine.

Biochem/physiol Actions

Dapoxetine is capable of blocking recombinant Kv4.3 potassium voltage-gated channels. It is considered as safe.
Potent Selective serotonin reuptake inhibitor (SSRI); used in treatment of premature ejaculation

Features and Benefits

This compound is featured on the Biogenic Amine Transporters page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Eli Lilly. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Pictograms

Exclamation mark
GHS07

Signal Word

Warning

Hazard Statements

H302,H319,H413

Hazard Classifications

Acute Tox. 4 Oral - Aquatic Chronic 4 - Eye Irrit. 2

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Chris G McMahon et al.
The journal of sexual medicine, 8(2), 524-539 (2010-11-10)
Dapoxetine has been evaluated for the on-demand treatment of premature ejaculation (PE) in five phase 3 studies in various populations worldwide and has recently been approved in several countries. To present integrated efficacy and safety data from phase 3 trials
Imju Jeong et al.
Naunyn-Schmiedeberg's archives of pharmacology, 385(7), 707-716 (2012-04-28)
The effects of dapoxetine were examined on cloned Kv1.5 channels stably expressed in Chinese hamster ovary cells using the whole-cell patch clamp technique. Dapoxetine decreased the peak amplitude of Kv1.5 currents and accelerated the decay rate of current inactivation in
Hartmut Porst
The journal of sexual medicine, 8 Suppl 4, 335-341 (2011-10-14)
With increasing interest and clinical research in male sexual disorders, it has become clear that not only psychological but also organic, neurobiological, and genetic factors may play an important role in premature ejaculation (PE). This article provides an overview of
W J G Hellstrom
International journal of clinical practice, 65(1), 16-26 (2010-12-16)
Current and upcoming treatment options for premature ejaculation (PE) are of global clinical interest. In 2008, the International Society for Sexual Medicine published an evidence-based definition for PE. While there are no US Food and Drug Administration-approved therapies for PE
Nicola Mondaini et al.
Urology, 82(3), 620-624 (2013-08-31)
To assess both the acceptance and the discontinuation rates from dapoxetine, the first oral pharmacological agent indicated for the treatment of premature ejaculation (PE). One hundred twenty consecutive potent patients (mean age 40.3 years; range 18-63 years) seeking medical treatment
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service